Category: Science

Scientists Talked To People In Their Dreams. They Answered

Staff ReporterEducation, Science 0

Researchers say two-way communication is possible with people who are asleep and dreaming.  Specifically, with people who are lucid dreaming — that is, dreaming while being aware you’re dreaming.

In separate experiments, scientists in the U.S., France, Germany and the Netherlands asked people simple questions while they slept. Sleepers would respond by moving their eyes or twitching their faces in a certain way to indicate their answers.

“Since the ’80s, we’ve known that lucid dreamers can communicate out of dreams by using these signals,” says Karen Konkoly, a Ph.D. student at Northwestern University who is the first author on the study published this month in Current Biology.

“But we were wondering, can we also communicate in? Can we ask people questions that they could actually hear in their dreams that we could kind of have a more meaningful conversation?”

They were studying rapid-eye-movement sleep, which is the stage of sleep where people dream most vividly. In REM sleep, “every muscle in your body is completely paralyzed, except you can twitch and you can move your eyes,” Konkoly tells Scott Simon on Weekend Edition. “So if you become lucid in a dream and you want to communicate, then when people are dreaming, they just look left-right, left-right, really dramatically. And then we know that they’re communicating out.”

Lucid dreaming is not common. So to study it, researchers recruited people who had experience with it and also trained people to try to make lucid dreaming more likely.

Before the participants went to sleep, they were also trained on how to communicate their answers. Special sensors measured people’s eye movements or experts would judge their facial movements.

For example, a typical question would be to ask what is 8 minus 6. A 19-year-old American man was able to respond by moving his eyes left-right, left-right — two times — to signal “2.” Researchers asked the question again, and he moved his eyes the same way two times again.

Out of the 158 trials among 36 participants, about 18% of the time, they were able to give correct answers. In another 18%, it wasn’t clear whether participants were responding or not. They were wrong 3% of the time. Most often, 61%, participants didn’t respond at all.

For the people dreaming, they didn’t always interpret the questions they were hearing as a simple question from researchers. “Sometimes stimuli were perceived as coming from outside the dream, but other times, the stimuli emanated from elements of the dream, contextualized in a way that made sense in relation to ongoing dream content,” the researchers write. One participant “heard the questions transposed over their dream as though it was God talking to them,” Konkoly says.

The researchers write that their findings present “new opportunities for gaining real-time information about dreaming, and for modifying the course of a dream” and “could usher in a new era of investigations into sleep and into the enigmatic cognitive dimensions of sleep.”

Konkoly says there’s the possibility of one day doing a sort of “dream therapy” for talking down people experiencing lucid nightmares.

And if more reliable communication methods can be worked out, it could help people with creative activities and ideas. “People often use lucid dreaming or dreaming for a kind of artistic, creative inspiration,” she says. “But in that dream state, your resources thus far are only the ones that you have in the dream.”

So with the help of an awake person, Konkoly says it could be possible to “combine those logical advantages of wake with the creative advantages of dreams and maybe have some more applications.”

(Samantha Balaban and Ed McNulty produced and edited the audio interview. Courtesy: NPR)

The COVID-19 Virus Is Mutating. What Does That Mean for Vaccines?

Staff ReporterEducation, Health, Science 0

As we enter the second year of living with the new coronavirus SARS-CoV-2, the virus is celebrating its invasion of the world’s population with yet more mutated forms that help it to spread more easily from person to person.

 

One, first detected in the U.K. in December, has already raised alarms about whether the COVID-19 virus is now escaping from the protection that vaccines just being rolled out now might provide. The variant has also been found in the U.S. Already, U.K. officials have tightened lockdowns in England, Scotland and Wales, and over the holidays, more than 40 countries banned travelers from the region in an effort to keep the new strain from spreading to other parts of the world.

 

Health officials are also concerned about a different strain found in South Africa that could become more resistant to vaccine protection. This variant includes a few mutations in key areas that antibodies, generated by the vaccine, target.

 

Exactly how the new strains affect people who are infected—such as whether they develop more severe symptoms—and whether they can lead to more hospitalizations and deaths, aren’t clear yet. But scientists are ramping up efforts to genetically sequence more samples from infected patients to learn how widespread they are. So far, there are enough hints to worry public health experts.

 

The fact that SARS-CoV-2 is morphing into potentially more dangerous strains isn’t a surprise. Viruses mutate. They must, in order to make up for a critical omission in their makeup. Unlike other pathogens such as bacteria, fungi and parasites, viruses have none of the machinery needed to make more copies of themselves, so they cannot reproduce on their own. They rely fully on hijacking the reproductive tools of the cells they infect in order to generate their progeny.

 

Being such freeloaders means they can’t be picky about their hosts, and must make do with whatever cellular equipment they can find. That generally leads to a flurry of mistakes when they sneak in to copy their genetic code; as a result, viruses have among the sloppiest genomes among microbes.

 

The bulk of these mistakes are meaningless—false starts and dead ends—that have no impact on humans. But as more mistakes are made, the chances that one will make the virus better at slipping from one person to another, or pumping out more copies of itself, increase dramatically.

 

Fortunately, coronaviruses in particular generate these genetic mistakes more slowly than their cousins like influenza and HIV—scientists sequencing thousands of samples of SARS-CoV-2 from COVID-19 patients found that the virus makes about two errors a month. Still, that’s led so far to about 12,000 known mutations in SARS-CoV-2, according to GISAID, a public genetic database of the virus. And some, by sheer chance, end up creating a greater public health threat.

 

Just a few months after SARS-CoV-2 was identified in China last January, for example, a new variant, called D614G, superseded the original strain. This new version became the dominant one that infected much of Europe, North America and South America. Virus experts are still uncertain over how important D614G, named for where the mutation is located on the viral genome, has been when it comes to human disease. But so far, blood samples from people infected with the strain show that the virus can still be neutralized by the immune system.

 

That means that the current vaccines being rolled out around the world can also protect against this strain, since the shots were designed to generate similar immune responses in the body. “If the public is concerned about whether vaccine immunity is able to cover this variant, the answer is going to be yes,” says Ralph Baric, professor or epidemiology, microbiology and immunology at University of North Carolina Chapel Hill, who has studied coronaviruses for several decades.

 

The so-called N501Y variant (some health officials are also calling it B.1.1.7.), which was recently detected in the U.K. and the U.S., may be a different story. Based on lab and animal studies, researchers believe this strain can spread more easily between people. That’s not a surprise, says Baric, since to this point, most of the world’s population has not been exposed to SARS-CoV-2.

 

That means that for now, the strains that are better at hopping from one person to another will have the advantage in spreading their genetic code. But as more people get vaccinated and protected against the virus, that may change. “Selection conditions for virus evolution right now favor rapid transmission,” he says. “But as more and more of the human population become immune, the selection pressures change. And we don’t know which direction the virus will go.”

 

In a worst case scenario, those changes could push the virus to become resistant to the immune cells generated by currently available vaccines. The current mutants are the virus’ first attempts to maximize its co-opting of the human population as viral copying machines. But they could also serve as a backbone on which SARS-CoV-2 builds a more sustained and stable takeover.

 

Like a prisoner planning a jailbreak, the virus is biding its time and chipping away at the defenses the human immune system has constructed. For example, the virus may mutate in a way that changes the makeup of its spike proteins—the part of the virus where the immune system’s antibodies attempt to stick to in order to neutralize the virus. And that one mutation may not be enough to protect the virus from those antibodies. But two or three might.

 

The biggest concern right now, says Baric, is that there are already two or three variants of SARS-CoV-2 that have mutations in just such places, “where additional mutations can make a more significant change in terms of transmissibility or virulence.”

The best way to monitor that evolution is by sequencing the virus in as many people who are infected, as often as possible.

 

Only by tracking how SARS-CoV-2 is changing can scientists hope to stay ahead of the most dangerous and potentially more lethal mutations. In Nov., the U.S. Centers for Disease Control (CDC) launched a sequencing program that will ask each state to send 10 samples every other week from people who have been infected, in order to more consistently track any changes in SARS-CoV-2’s genome. But it’s a voluntary program. “It’s still not a national effort, it’s voluntary, and there is no dedicated funding for it,” says Baric.

 

“Come on, we’re in the 21st century—let’s enter the 21st century.”

Without substantial federal funding dedicated specifically to sequencing SARS-CoV-2 genomes, most of the work in the U.S. is currently being done by scientists at academic centers like the Broad Institute of MIT and Harvard and the University of Washington. Since early last year, the CDC has been working to better characterize SARS-CoV-2 viruses from patient samples in partnership with some of these academic labs, as well as state and local health departments and commercial diagnostic companies, in the SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance (SPHERES) consortium.

 

“If we sequence one out of 200 cases then we’re missing a lot of information,” says Baric. “If we’re sequencing about 20% of cases, then we might start to see something and we would be in the ball game to find new variants. We probably could be doing a better job of that here in the U.S.”

 

Other countries are also working on this effort. The U.K. has long been a leader in genetic sequencing, and likely because of their efforts were able to identify the new variant relatively quickly after it emerged. Globally, scientists have also been posting genetic sequences from SARS-CoV-2 to the public GISAID database.

 

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, and chief medical advisor to President-elect Joe Biden, says that his teams are sequencing and studying the new variants to better understand what effect they might have on disease, how close they might be to causing more severe illness and, more importantly as more people get vaccinated, whether the new variants can escape the protection of the vaccines we know work today.

The good news is that if the mutant strains do become resistant to the current vaccines, the mRNA technology behind the Pfizer-BioNTech and Moderna should enable the companies to develop new shots without the same lengthy developing and testing that the originals required. “The mRNA platform is eminently flexible to turn around,” says Fauci.

 

If a new vaccine were needed, it would be treated by the Food and Drug Administration as a strain change in the virus target, similar to how flu shots are modified every year. “You could get that out pretty quickly,” says Fauci, after showing in tests with a few dozen people that the new vaccine produced satisfactory amounts of antibodies and protection against the mutant virus.

 

Tracking every change the virus makes will be critical to buying the time needed to shift vaccine targets before SARS-CoV-2 leaps too far ahead for scientists to catch up. “We are taking [these variants] seriously and will be following them closely to make sure we don’t miss anything,” says Fauci.

Swati Mohan At NASA’s Perseverance Rover Mission

Staff ReporterScience, Women 0

When NASA’s Perseverance rover gently touched down on the surface of Mars on Thursday after seven months in space, it was an Indian-American named Dr. Swati Mohan, who first confirmed that the rover had survived a particularly tricky plunge into the Martian atmosphere.

 

“Touchdown confirmed! Perseverance is safely on the surface of Mars, ready to begin seeking the signs of past life,” a calm and composed bindi-clad Mohan announced soon after the rover landed, as cheers erupted in NASA’s mission control room in California.

 

Mohan, who successfully spearheaded the development of attitude control and the landing system for the rover, was among the team of scientists behind the historic mission. The attitude control system is responsible for pointing the rover in the direction it needs to be and also helps figure out where the spacecraft is oriented in space.

 

The Cornell graduate has been associated with the Perseverance Mars Mission since its inception and has been part of a number of other NASA missions over the years. Notably, she also worked on NASA’s Cassini mission to Saturn.

 

On Thursday, Mohan made history yet again, when she steered the controls and landing system of the rover and navigated a rather difficult touchdown, while the whole world watched with bated breath.

 

The NASA scientist first emigrated from India to the United States when she was just a year old. Most of her childhood was spent in the Northern Virginia-Washington DC area. Mohan traces her love for space back to the American science fiction series ‘Star Trek’, which she first watched at the age of 9. While she wanted to become a paediatrician until she was 16, she later decided to become an engineer and pursue her interest in space exploration.

 

Not only is Mohan a pivotal player in the effort to determine whether there was ever life on the red planet; she’s also a reflection of the progress NASA has made in reflecting the nation it represents.

 

Her passion for space started with ‘Star Trek’

 

Mohan has been interested in space ever since she saw her first “Star Trek” television episode at age 9. It opened up her world to the beauty and expanse of the universe.

“I remember thinking ‘I want to do that. I want to find new and beautiful places in the universe,'” she recalled in a Q&A on NASA’s website. “The vastness of space holds so much knowledge that we have only begun to learn.”

 

Still, she thought she would grow up to become a pediatrician. It wasn’t until she took her first physics class at age 16 that she began considering a career in engineering, which would allow her to follow her childhood dreams of exploring space.

Mohan went on to study mechanical and aerospace engineering at Cornell University, followed by a masters degree and doctorate in aeronautics and astronautics at the Massachusetts Institute of Technology. Eventually, she landed at NASA.

Before her work on Perseverance, Mohan was a part of space exploration efforts such as Cassini, a spacecraft that unearthed countless discoveries about Saturn, and GRAIL, a mission that sent twin spacecraft around the moon.

 

She started working on the Mars 2020 mission in 2013, and ultimately became the lead engineer for guidance, navigation and controls operations. She helmed the mission’s attitude control system, which helps make sure the spacecraft is heading in the direction it needs to be.

 

“During the cruise phase heading toward Mars, our job is to figure out how we are oriented, make sure the spacecraft is pointed correctly in space (solar arrays to sun, antenna to Earth), and maneuver the spacecraft to get it where we want to go,” Mohan explained in a NASA Q&A. “During entry, descent, and landing on Mars, GN&C determines the position of the spacecraft and commands the maneuvers to help it land safely.”

 

And on Thursday, she was one of two voices heard in the control room and around the world — explaining major milestones in NASA’s first mission to search for signs of life on another planet.

 

“I’ve been on Perseverance longer than I’ve been at any school,” Mohan told the newspaper Florida Today. “I’ve been on Perseverance longer than my younger daughter is alive. It’s just taken up such a large portion of my life for so long.”

This was a diverse mission

 

It wasn’t just Mohan, either.  The Perseverance rover mission was diverse by a number of measures: race, gender and sexuality. That the team behind the historic spacecraft included folks like landing lead Allen Chen, and engineers such as Moogega Cooper, Cj Giovingo and Gregorio Villar, shows it was representative of the nation’s demographics.

 

That array of names and faces is a sign of the progress NASA has made since it was founded in 1958. White men were long seen as the face of the space exploration program, despite significant contributions from women and people of color over the years. The agency had only ever selected White men as astronauts until 1978, when it admitted a class that included the first female, first African American and first Asian American astronauts.

 

There is still progress to be made, but NASA’s workforce now looks much more like the nation.  Of the more than 17,000 people who work for NASA, 72% are White, 12% are Black, 8% are Asian American or Pacific Islander, 7% are Hispanic or Latino, 1% are American Indian or Alaska Native and less than 1% are more than one race, according to agency data

Rover Touches Down On Mars In Search Of Past Life Form

Staff ReporterScience 0

Nasa’s Perseverance, the most advanced robotic rover ever sent to Mars, touched down safely on an ancient lakebed in the Jezero Crater on the Red Planet on Thursday, seven months after it was launched from Florida. NASA dubbed the spacecraft’s descent and landing during a complex series of man oeuvres “the seven minutes of terror”.

 

The robotic vehicle sailed through space for nearly seven months, covering 293m miles (472m km) before piercing the Martian atmosphere at 12,000mph (19,000km/h) to begin its approach to touchdown on the planet’s surface.

 

The six-wheeled Perseverance, weighing about 1,025 kilograms, will search for signs of past organisms in the first life hunt conducted on the Martian surface since NASA’s twin Viking landers ceased operations in the early 1980s. Note: Perseverance is focused on life forms from the distant past.

 

Jezero Crater is a good bet, explains Space.com, as it has hosted a lake the size of Lake Tahoe long ago and also sports an ancient river delta. Perseverance will collect about 40 samples from promising sites and seal them inside special tubes. This material will then be brought back to Earth by a joint NASA-European Space Agency campaign, perhaps as early as 2031.

 

Perseverance’s payload also includes demonstration projects that could help pave the way for eventual human exploration of Mars, including a device to convert the carbon dioxide into pure oxygen. Such equipment, if scaled up, could help humanity get a foothold on Mars down the road, NASA said.

 

Another round of cheers and applause erupted in the control room as the images of the surface arrived minutes after touchdown. Partially obscured by a dust cover, the first picture was a view from one of the Perseverance’s hazard cameras. It showed the flat, rocky surface of the Jezero crater.

A second image taken by a camera on board the spacecraft showed a view from behind the rover of the Jezero crater. The rover appeared to have touched down about 32 metres (35 yards) from the nearest rocks.

“It really is the beginning of a new era,” Nasa’s associate administrator for science, Thomas Zurbuchen, said earlier in the day during Nasa’s webcast of the event.

Extreme Life Beneath Antarctica’s Ice Shelves Poses Several Questions

Staff ReporterEnvironment, Science 0

Dr. Huw Griffiths, marine biologist and lead author of the study, said that the stationary animals are like sponges and potentially several previously unknown species. The discovery appears to go against all previous theories of what kind of life could survive in such an extreme condition.(British Antarctic Survey)

 

Researchers accidentally discovered extreme life far underneath the ice shelves of the Antarctic during an exploratory survey, a recent study published in the journal Frontiers in Marine Science said. At a distance of 260km away from the open ocean, the researchers found out the existence of stationary animals attached to a boulder on the seafloor as they drilled through 900 metres of ice in the Filchner-Ronne Ice Shelf with their cameras lowered down.

 

Dr Huw Griffiths, marine biologist and lead author of the study, said that the stationary animals are like sponges and potentially several previously unknown species. In a video shared by the British Antarctic Survey, Griffiths said it was a surprising discovery because they never expected animals that “filter feed their food from the water column to be found this far from a source of food or daylight.”

 

“This discovery is one of those fortunate accidents that pushes ideas in a different direction and shows us that Antarctic marine life is incredibly special and amazingly adapted to a frozen world,” the biogeographer said in a separate statement.

 

The first-ever record of a hard substrate community deep beneath an ice shelf throws up more questions than it answers since the researchers don’t know how did they get there, what they have been eating or how long they have been there. The researchers are wondering whether these are the same species seen outside the ice shelf or are they new species. There are also few questions around the survival of these species in case the ice shelf collapses.

 

The discovery appears to go against all previous theories of what kind of life could survive in such an extreme condition. The dependence on drilling and cameras mean, according to Griffiths, the area underneath the giant floating ice shelves is probably one of the least known habitats on Earth. But getting up close with these animals and their environment remains a challenge for polar scientists.

 

“We have no idea what species these animals are. We don’t know how they are coping with these extreme conditions. And the only way we are going to be able to answer those questions is to come up with a new way of investigating their world,” added Griffiths.

Humans Versus Earth: The Quest To Define The Anthropocene

Meera SubramanianEnvironment, News, Science 0

Crawford Lake is so small it takes just 10 minutes to stroll all the way around its shore. But beneath its surface, this pond in southern Ontario in Canada hides something special that is attracting attention from scientists around the globe. They are in search of a distinctive marker buried deep in the mud — a signal designating the moment when humans achieved such power that they started irreversibly transforming the planet. The mud layers in this lake could be ground zero for the Anthropocene — a potential new epoch of geological time.

 

This lake is unusually deep for its size so its waters never fully mix, which leaves its bottom undisturbed by burrowing worms or currents. Layers of sediment accumulate like tree rings, creating an archive reaching back nearly 1,000 years. In high fidelity, it has captured evidence of the Iroquois people, who cultivated maize (corn) along the lake’s banks at least 750 years ago, and then of the European settlers, who began farming and chopping down trees more than five centuries later. Now, scientists are looking for much more recent, and significant, signs of upheaval tied to humans.

 

Core samples taken from the lake bottom “should translate into a razor-sharp signal”, says Francine McCarthy, a micropalaeontologist at nearby Brock University in St Catherines, Ontario, “and not one blurred by clams mushing it about.” McCarthy has been studying the lake since the 1980s, but she is looking at it now from a radical new perspective.

 

Crawford Lake is one of ten sites around the globe that researchers are studying as potential markers for the start of the Anthropocene, an as-yet-unofficial designation that is being considered for inclusion in the geological time scale. The Anthropocene Working Group (AWG), a committee of 34 researchers formed by the International Commission on Stratigraphy (ICS) in 2009, is leading the work, with the aim of crafting a proposal to formally recognize the Anthropocene. This new epoch would mark a clear departure from the Holocene, which started with the close of the last ice age. To define a new epoch, the researchers need to find a representative marker in the rock record that identifies the point at which human activity exploded to such a massive scale that it left an indelible signature on the globe.

 

Given how much people have done to the planet, there are many potential markers. “Scientifically, in terms of evidence, we’re spoiled for choice, but we have to pin it down,” says Jan Zalasiewicz, a palaeobiologist at the University of Leicester, UK, and chair of the AWG.

 

The committee’s current plan is to look to the legacy of the atomic age, when radioactive debris from mid-twentieth-century nuclear bomb blasts left a fingerprint of radioisotopes in the atmosphere, rocks, trees and even humans. “There’s a big bomb spike somewhere between 1952 and 1954 that is quite distinct and unmistakable,” says Zalasiewicz.

Once they pick their representative marker, researchers working with the AWG need to gather enough evidence from around the world to convince the governing bodies of geoscience that they have found a truly reliable signal for the start of the Anthropocene.

 

But some scientists argue that human activity has been shaping the planet for thousands of years, and that the working group has settled too quickly on the 1950s for the start of the proposed epoch. Erle Ellis, a geographer at the University of Maryland, Baltimore County, and an AWG member, has criticized the committee’s plans for designating the start of the Anthropocene. “The AWG decided the timing of the boundary before deciding on the marker, not the other way around,” says Ellis.

Hard evidence

 

In the end, it will be the rocks that have the final say. The decision on whether to officially designate the Anthropocene will come down to stratigraphic evidence preserved in the geological record — that is, whether humans have left a distinctive set of marks preserved in rock, seafloor mud or glacial ice that indicates a fundamental change in the planet.

 

After a decade of investigating this question, the AWG decided in May that humans had, in fact, left an indelible geological mark. In a binding vote in May, 29 of the 34 members opted to move forward with developing a proposal supporting the designation of the Anthropocene.

The AWG’s next task is to put forward a formal proposal identifying a global boundary stratotype section and point (GSSP), or ‘golden spike’ (see C. N. Waters et al. Earth Sci. Rev. 178, 379–429; 2018). A GSSP is a primary geological marker at one location that can be correlated with sites around the globe in diverse environments. The Anthropocene’s golden spike needs to demonstrate that there was a globally synchronous moment when physical, chemical and biological processes amounted to the irreversible crossing of a geological threshold from the Holocene to something altogether different.

In its recent vote, the AWG members decided overwhelmingly to pursue a GSSP in the mid-twentieth century. This time marks the start of the ‘Great Acceleration’, a vast transformation after the Second World War when the growing population began consuming resources and creating completely new materials at an exponential rate, eclipsing even the Industrial Revolution. All that activity poured unprecedented amounts of persistent organic pollutants into the environment, ramped up the rate of animal extinctions and created geological features that had never before existed.

 

These include 4-kilometre-deep gold mines and landfills more than 70 metres high, such as Teufelsberg in Berlin, where rubble from the Second World War was piled into an artificial hill. Although the AWG is still exploring several potential golden spikes, the radioactive record from the nuclear age has emerged as the front runner. “Radionuclides still look like the sharpest signal,” says Zalasiewicz. The AWG summed up its current work in The Anthropocene as a Geological Time Unit, published in February by Cambridge University Press.

Protein Slowing Down Covid Spread In Asia?

Staff ReporterEducation, Health, Science 0

A team of scientists from the National Institute of Biomedical Genomics in Kalyani, West Bengal, have found a biological reason for the slower spread of a mutant of coronavirus in Asia compared to the West. They explained how higher levels of a human protein — neutrophil elastase — helps the virus to enter the human cell, multiply and also spread faster from infected individuals.

However, this protein is kept in check by the biological system, which produces another protein called alpha-1 antitrypsin (AAT). AAT deficiency leads to higher levels of neutrophil elastase in the cells, which in turn helps in faster spread of the virus. This deficiency is known to be much higher in Europe and America than among Asians. The study has been published in the journal Infection, Genetics and Evolution.

The team of scientists led by Nidhan Biswas and Partha Majumder observed that the rate of the spread of the mutant virus — D614G — has been non-uniform across geographical regions. The researchers say that, “…in order to reach 50% relative frequency, the 614G subtype took significantly longer time in East Asia (5.5 months) compared to Europe (2.15 months) as well as North America (2.83 months).”

The researchers linked the differential spread to an additional cleavage site created by the D614G mutant virus, for entry into the human cell.

“However, some naturally-occurring mutations in the AAT-producing gene results in deficiency of the AAT protein,” said Majumder. “This deficiency is known to be much higher in the Caucasians of Europe and America than among Asians. While we used AAT deficiency data from East Asia, along with North America and Europe, for the study, considering the pace at which the coronavirus is spreading, the numbers are representative of other Asian regions too, including India.”

Per their data, AAT deficiency is the least in East Asian countries — 8 per 1,000 individuals in Malaysia, 5.4 per 1,000 in South Korea, 2.5 in Singapore. On the other hand, 67.3 in per 1,000 individuals in Spain are AAT deficient, 34.6 in the UK and 51.9 in France and in the US it is prevalent in 29 individuals among 1,000.

Scientists Design Rotation Profile Of The Sun Based On Century-Old Sunspot Images

Staff ReporterScience 0

A team of international solar researchers, led by Bibhuti Kumar Jha, a PhD scholar from Aryabhatta Research Institute of Observational Sciences (ARIES) in Nainital, has designed a rotation profile of the Sun after studying the varying behaviours of sunspots observed over 100 years. Sunspots are small and dark but cooler areas on the solar surface having strong magnetic forces.

The solar rotation profile is based on the fact that the bigger sunspots rotate at a slower rate in comparison to the smaller ones. “The presence of strong magnetic fields around bigger sunspots prevents them from having a faster rotation rate. This, as opposed to smaller sunspots which possess a comparatively less intense magnetic field allowing it to rotate faster,” Jha said.

Researchers at ARIES, in collaboration with their counterparts at Max Planck Institute for Solar System Research, Germany and Southwest Research Institute, US, studied several thousand digitised images of sunspot images retrieved from older photographs and films. The images were generated by the Kodaikanal Solar Observatory (KoSO) between 1923 and 2011.

Run by the Indian Institute of Astrophysics, Bengaluru, KoSO has a repository of about 4 lakh images of the Sun recorded since 1904. All of them have been digitised in the recent years.

Unlike Earth — a solid mass of body having uniform rotation, the Sun has differential rates of rotation. This means, the solar equator rotates faster than its poles. The scientists have attempted to precisely track sunspots at various latitudes of the Sun in order to understand the rotational behaviours at different latitudes.

Besides, sunspots and solar cycles have helped scientists understand the Sun’s behaviour from the past. These continue to remain observable characters to predict the Sun’s future. However, what makes the tracking of sunspots challenging is the time and the position on the Sun’s surface. Generally, they start appearing at higher latitudes and later shift towards the equator as the solar cycle (which spans 11 years) progresses.

“We do not see sun spots across all latitudes at all times. As sunspots do not appear beyond 45 degrees latitude, sunspots are not formed around the poles,” Dipankar Banerjee, director, ARIES, and a collaborator in the study, told The Indian Express.

Due to limited camera resolution at the time of image capturing during telescope observations, results from several past studies were based only on larger sun spots. But the KoSO image data-set featured sun spot images captured in all sizes. “Even using the dynamo models, the rate of differential rotation still remains unestablished,” Banerjee added.

Contrary to what is believed, no variation in rotation rates was noted between solar activity extremes, that is, between a solar maxima and minima, the researchers confirmed.

If one can understand solar dynamo, it can give a better insight into the solar cycle which in turn, will help predict how the Sun will behave in future, Jha said.

 

UAE’s Historic Mission To Mars

Staff ReporterScience 0

The UAE has become the fifth country after the US, Russia, China, the EU, and India, to reach the Martian orbit. The primary objective of the mission is to study Martian weather dynamics.

The United Arab Emirates’ first mission to Mars entered the orbit of the red planet on Tuesday, seven months after the Emirati-built ‘Hope Probe’ was launched from Tanegashima in Japan. With this, the UAE has become the fifth country after the US, Russia, China, the EU, and India, to reach the Martian orbit.

Relieved ground controllers at the UAE’s space station in Dubai broke into applause after the unmanned spacecraft called ‘Al-Amal’ — the Arabic word for hope — executed a ‘burn’ on its braking engines to reduce speed and successfully slipped into Mars’ gravity.

“What you have accomplished is an honour for you, and an honour for the nation. I want to congratulate you,” said Abu Dhabi Crown Prince Sheikh Mohammed bin Zayed after entering the control room, AFP reported. The historic event was timed to coincide with the 50th anniversary of the unification of the UAE’s seven emirates.

What is the UAE’s Hope Probe?

First announced in July 2014, the Emirates Mars Mission was developed and operated by the Mohammed Bin Rashid Space Centre in collaboration with the University California, Berkeley, Arizona State University and the University of Colorado-Boulder in the United States.

In July 2020, it was launched from the Tanegashima Space Centre in Japan aboard a Mitsubishi Heavy Industries’ H-II A rocket and its launch became the 45th for H-II A. Carrying three instruments, including a high-resolution camera and a spectrometer, the spacecraft is on an orbital mission to collect data on Martian climate dynamics and help scientists understand why Mars’s atmosphere is decaying into space.

Hope is the UAE’s fourth space mission and first interplanetary one. The previous three were all Earth-observation satellites. Once it is successfully able to reach the planet, it will start orbiting the planet. Its overall mission life is one Martian year, which is about 687 days on Earth.

The mission is one of three launched to Mars from Earth in July. The other two — China’s Tianwen-1 dual orbiter-rover and Perseverance from NASA — are expected to reach the red planet later this month. While Hope was the first to arrive, Tianwen-1 will reach on February 10, followed by Perseverance on February 18.

he timing of the mission is crucial as it was launched at a time when Earth and Mars were aligned at their closest points around the Sun, the Verge reported.

What is the objective of the mission?

The primary objective of the mission is to study Martian weather dynamics. By correlating the lower atmosphere and upper atmosphere conditions, the probe will look into how weather changes the escape of hydrogen and oxygen into space.

By measuring how much hydrogen and oxygen is spilling into space, scientists will be able to look into why Mars lost so much of its early atmosphere and liquid water. Over the next two months, the spacecraft will continue to move into its final orbital position — around 20,000-43,000 kilometres about the planet. The distance is calculated in a way that allows the craft to use all three instruments to capture a complete view of the Martian atmosphere every nine days for the next two years.

It is expected to create the first complete portrait of the planet’s atmosphere. With the information gathered during the mission, scientists will have a better understanding of the climate dynamics of different layers of Mars’ atmosphere.

Al-Amal will be the first “true weather satellite” orbiting around the planet. But the UAE also wants the mission to inspire the country’s youth to take up careers in the sciences. The government also hopes that the mission will boost the UAE’s science and technology sector.

 

Age-Related Macular Degeneration: Poised For A New Treatment Era

Staff ReporterHealth, Science 0

Newswise — SAN FRANCISCO – For more than a decade, ophthalmologists have treated wet age-related macular degeneration (AMD) with eye injections given every month or two, and dry AMD with antioxidant vitamins. These treatments were groundbreaking when introduced, offering hope for the first time that this sight-threatening disease could be slowed, and in some cases stopped or even reversed. As we mark February as AMD Awareness Month, the American Academy of Ophthalmology is highlighting what the next decade may hold for the 11 million Americans suffering from AMD.

The good news is that AMD treatment continues to evolve to the benefit of patients. Ophthalmologists expect to soon have more effective options to protect people from going legally blind from AMD.

“While our current treatments have made a huge difference in the lives of hundreds of thousands of people, new treatments offer hope to patients whose AMD previously could not be treated,” said Sunir J. Garg, MD, FACS, a retina specialist and clinical spokesperson for the American Academy of Ophthalmology. “New treatments will also help patients receive beneficial treatment more conveniently than ever before.”

The following is a review of the most promising research.

Dry AMD

Dry AMD can be divided into three forms: early, intermediate, and late. For those with intermediate disease, a formulation of antioxidant vitamins called the AREDS2 formula can help many patients reduce their risk of vision loss. But for those with late-stage disease, also called geographic atrophy, there is no treatment available. However, there are several promising clinical trials underway.

  • Targeting the immune system A part of the immune system called the “complement cascade” has long been identified as a culprit in AMD. Two new drugs that target the complement cascade and stop it from attacking the retina have recently advanced to late-stage clinical trials. One (pegcetacoplan, APL-2) targets a complement protein called C3, the other drug candidate (Zimura, avacincaptad pegol) targets a different protein in the cascade, C5. Like currently available treatments for wet AMD, these drugs are injected directly into the patient’s eye. Already proven safe in people, researchers are now investigating whether they can substantially improve vision. Results are expected in about a year.
  • Replacing vision cells Another concept under investigation is the possibility of replacing some cells that begin to die in late dry AMD. These retinal pigment epithelial cells can be produced from stem cells and then placed under the retina during a surgical procedure. Trials have shown that cell replacement did not have unexpected side effects. Additional trials are now evaluating whether it can actually improve vision. Even though intriguing investigations are progressing, stem cell treatments still have a long way to go before approval.

Wet AMD

Before anti-VEGF treatments were introduced about 15 years ago, people with wet AMD were almost certain to develop severe vision loss or blindness. While clinical trials show that anti-VEGF injections have allowed more than 90 percent of patients to keep their vision, in the real world the percentage is closer to 50 percent. That’s because people aren’t being treated as regularly as they should. The problem is most people need an injection every four to eight weeks to keep their vision. This can be a difficult schedule to maintain for many elderly patients struggling with other maladies and reliant on others to get them to their ophthalmology visits.

Some of the most exciting research today is looking at better alternatives to frequent injections. It’s not just about convenience; the hope is that a more consistent treatment will also help people keep more of their vision.

  • New delivery methods One promising approach that could be available soon is a refillable drug reservoir. The device, about the size of a grain of rice, is surgically implanted in the eye, just under the eyelid. After the device is filled with a concentrated version of the anti-VEGF drug Lucentis, it delivers drug to the back of the eye over time. Instead of an injection every six to eight weeks, patients might get a fill up once or twice a year at the doctor’s office. The device can be refilled using a special needle. The latest studies show many people treated this way were able to go 15 months in between treatments.
  • Gene therapy Gene therapy offers the hope of a potential “one-and-done” treatment. Researchers are using already proven gene therapy methods to deliver a treatment that enables the eye to make its own anti-VEGF medicine. Two different methods are under investigation: One injects the gene therapy underneath the retina in a surgical procedure; the other injects it into the eye just like a routine anti-VEGF treatment is done in the doctor’s office. There are four different drug candidates under investigation for wet AMD and one for dry AMD. Despite the promise of gene therapy, the long-term effectiveness remains to be seen. Among the challenges it faces is the likely sky-high cost of such a treatment.
  • New targets Anti-VEGF treatments are effective because they target one key factor that contributes to wet AMD, vascular endothelial growth factor (VEGF). But what if a drug could target two key contributing factors to the development of AMD? That’s the idea behind the drug faricimab. It targets both VEGF and the protein angiopoietin-2. It’s injected into the eye like a standard anti-VEGF treatment, but it lasts longer. The latest research shows patients could go up to four months in between treatments. However, this data is so new that it has not yet been published in a peer-reviewed journal.

“This is an exciting time for clinical research for age-related macular degeneration that gives hope to many of our patients,” said Rahul N. Khurana, a retina specialist and clinical spokesperson for the American Academy of Ophthalmology. “For dry AMD patients suffering from vision loss, there may be treatments on the horizon. For wet AMD, there are new delivery options with longer duration of action and new molecular targets that may lead to more effective therapies.”

The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit aao.org.

Dr. Mathai Mammen, J&J’s Global Head Of Research And Development, Is Confident Of Its Covid Vaccine

Staff ReporterHealth, Profile, Science 0

A third Covid-19 vaccine, one made by Johnson & Johnson, could be authorized for use in the United States in the near future. The vaccine was made through a collaboration of J&J’s Belgium-based vaccine division, Janssen Pharmaceutical, and Beth Israel Deaconess Medical Center, and it works a bit differently.

The company will apply for an EUA “middle to late next week,” Dr. Mathai Mammen, Janssen’s global head of research and development, said during a call with reporters last week. The call was held along with officials from the National Institutes of Health. Janssen is the vaccine arm of Johnson & Johnson. If the vaccine is authorized for emergency use, Mammen said, “Our plan is to have supply immediately upon launch.” 

Once an application is submitted, “The FDA really looks very, very carefully at the data in each age group and in each demographic group,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said during the call.

 

Data about the single-shot vaccine released, and the company is now collating its data to apply to the US Food and Drug Administration for emergency use authorization. Here’s what’s known about how it works and how it will fit into the mix of vaccines.

How effective is it?

Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, the company announced Friday.

The vaccine is 85% effective overall at preventing hospitalization and death in all regions where it was tested.

Its efficacy against moderate and severe disease ranged from one country to another: 72% in the US, 66% in Latin America and 57% in South Africa. This was measured starting one month after the shot.

In South Africa, 95% of cases in the trial were due to a variant known as B.1.351, which is known to be more contagious and carries mutations that may make the virus less susceptible to the antibody immune response — including antibodies prompted by vaccination.

Even those who got moderate cases of Covid-19 in the trial tended to develop a milder course and fewer symptoms, said Dr. Mathai Mammen, Janssen’s global head of research and development. From one month after the shot, all hospitalizations and deaths occurred in the placebo group.

How it works

The J&J vaccine is what is known as a non-replicating viral vector vaccine, using a common cold virus called adenovirus 26. Scientists made this vaccine by taking a small amount of genetic material that codes for a piece of the novel coronavirus and integrating it with a weakened version of adenovirus 26. J&J scientists altered this adenovirus so it can enter cells, but it cannot replicate and make people sick. 

AstraZeneca uses a similar platform, but its adenovirus comes from a chimpanzee. The adenovirus carries the genetic material from the coronavirus into human cells, tricking them into making pieces of the coronavirus spike protein — the part it uses to attach to cells. The immune system then reacts against these pieces of the coronavirus.

“So you’re not being infected with the virus that can give you Covid-19 when you get this vaccine. It just has some of the harmless Covid virus proteins on its surface,” explained Dr. William Schaffner, an internist and infectious disease specialist with Vanderbilt University’s Department of Health Policy. “So essentially it’s a sheep in wolf’s clothing, and when your immune system sees it, it responds to it and creates protection against it and in the future, against the real virus that causes Covid-19.”

The technology used in the Covid-19 vaccine has worked with the Ebola vaccine by Janssen.

How is it different from the other Covid-19 vaccines?

Dr. Paul Offit, the director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said the Moderna, Pfizer and J&J Covid-19 vaccines all take a similar approach, but there is a small difference with the J&J approach.

“In the case of the Moderna and Pfizer vaccine you’re just giving the gene in a lipid nanoparticle or a fat droplet,” Offit said. “In the case of J&J you’re giving the gene in a virus that can’t reproduce itself.”

The J&J vaccine is the only Covid-19 vaccine so far to be given in a single dose. Moderna and Pfizer’s use two. Like Moderna’s, it can also be kept at regular refrigerated temperatures and does not need a deep freeze like Pfizer’s.

How does a single-dose shot affect the rollout?

A single dose and would be much easier to administer and would mean more people could be vaccinated, as none would need to be set aside to give someone a second shot. 

“This advantage goes up in neon,” said Schaffner who believes adding a vaccine like this would “really accelerate” vaccination efforts in the US and around the world.

“If it’s a single-dose vaccine, then a billion vaccine doses would translate into a billion people vaccinated,” said Dr. Dan Barouch of Harvard Medical School, who helped develop Johnson & Johnson’s vaccine candidate on CNN’s Coronavirus Fact vs. Fiction podcast.

The cold-chain advantage 

J&J’s other advantage is that it can be stored at regular refrigerator temperatures, unlike the Pfizer vaccine, which needs special deep freezers. The vaccine is stable for up to three months at 36 degrees F to 46 degrees F, the company said. That means health care facilities would not have to buy extra equipment to safely store the vaccine.

“If they’re successful, these vaccines would especially be popular in the developing world, because they would be easy to store and administer,” said Dr. Rafi Ahmed, the director of the Vaccine Center at Emory University.

The vaccines would also be popular in rural communities in the US and regular doctor’s offices that may not have access or the budget to afford specialized equipment.

“In other words, we could bring the vaccine to the people,” Schaffner said, “rather than bringing the people to the vaccine.”

What happens next?

The company will request what’s known as an emergency use authorization, or an EUA, from the FDA in early February. The data will get a close look from the FDA and advisers to the US Centers for Disease Control and Prevention.

While the FDA is reviewing the data, it schedules a public meeting of its Vaccines and Related Biological Products Advisory Committee. The committee is made up of independent science and public health experts who will discuss the J&J data and make a recommendation to the agency.

Once an application is submitted, “The FDA really looks very, very carefully at the data in each age group and in each demographic group,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said during a call on Friday.

After the meeting, FDA staff members consider the committee input along with the agency’s evaluation of the company’s data and will make a decision about whether the vaccine should by authorized.

Shortly after an EUA, the CDC’s Advisory Committee on Immunization Practices, also known as ACIP, goes through the data, too.

Once the CDC committee has made a recommendation and it has been approved by the CDC director, the company plans to ship the vaccines immediately and it can go into arms right away.

How long does the authorization process take?

The process for the Johnson & Johnson vaccine should be about the same as it was for the Moderna and Pfizer vaccines, according Offit, who is a member of the FDA’s VRBPAC.

With the Pfizer vaccine, it took a little over three weeks from the time the company submitted its data to an EUA. With the Moderna vaccine, it took a little more than two weeks.

If the vaccine is authorized for emergency use, “our plan is to have supply immediately upon launch,” Mammen said.

How many doses are there?

The US has ordered 100 million doses and the company has been manufacturing it while it has been testing the vaccine. Typically, companies wait to make the vaccine after its been approved, but that changed during the pandemic.  Johnson & Johnson says it can meet its 100 million dose commitment by June.

Dr. Mammen’s mission is to work with the best research and development professionals in the world to make meaningful medicines that impact the lives of patients, their families and communities.

Prior to joining Janssen in June 2017, Dr. Mammen was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/Immuno-Oncology and Immunology. Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. He also nucleated a new discovery site in the San Francisco Bay Area.

Prior to Merck, Dr. Mammen led R&D at Theravance, a company he co-founded in 1997 based on his work at Harvard University. Under his leadership, the Theravance team of 200 scientists nominated 31 development candidates in 17 years, created three approved products (Breo®, Anoro®, Vibativ®), two additional assets that have successfully completed Phase 3 studies and a pipeline containing 11 further development-stage compounds in 2016. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva (INVA) and Theravance Biopharma (TBPH).

Dr. Mammen has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry, working with George Whitesides. He received his BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

(Courtesy: CNN’s Amanda Sealy, Jacqueline Howard and Maggie Fox)

The Rate Of The Universe’s Expansion Explained

Staff ReporterEducation, Science 0

Newswise —A combination of astrophysical measurements has allowed researchers to put new constraints on the radius of a typical neutron star and provide a novel calculation of the Hubble constant that indicates the rate at which the universe is expanding.
“We studied signals that came from various sources, for example recently observed mergers of neutron stars,” said Ingo Tews, a theorist in Nuclear and Particle Physics, Astrophysics and Cosmology group at Los Alamos National Laboratory, who worked with an international collaboration of researchers on the analysis to appear in the journal Science on December 18. “We jointly analyzed gravitational-wave signals and electromagnetic emissions from the mergers, and combined them with previous mass measurements of pulsars or recent results from NASA’s Neutron Star Interior Composition Explorer. We find that the radius of a typical neutron star is about 11.75 kilometers and the Hubble constant is approximately 66.2 kilometers per second per megaparsec.”
Combining signals to gain insight into distant astrophysical phenomena is known in the field as multi-messenger astronomy. In this case, the researchers’ multi-messenger analysis allowed them to restrict the uncertainty of their estimate of neutron star radii to within 800 meters.
Their novel approach to measuring the Hubble constant contributes to a debate that has arisen from other, competing determinations of the universe’s expansion. Measurements based on observations of exploding stars known as supernovae are currently at odds with those that come from looking at the Cosmic Microwave Background (CMB), which is essentially the left over energy from the Big Bang. The uncertainties in the new multimessenger Hubble calculation are too large to definitively resolve the disagreement, but the measurement is slightly more supportive of the CMB approach.
Tews’ primary scientific role in the study was to provide the input from nuclear theory calculations that are the starting point of the analysis. His seven collaborators on the paper comprise an international team of scientists from Germany, the Netherlands, Sweden, France, and the United States.
Los Alamos National Laboratory, a multidisciplinary research institution engaged in strategic science on behalf of national security, is managed by Triad, a public service oriented, national security science organization equally owned by its three founding members: Battelle Memorial Institute (Battelle), the Texas A&M University System (TAMUS), and the Regents of the University of California (UC) for the Department of Energy’s National Nuclear Security Administration.
Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health, and global security concerns.

Biden Leads the Way with Receiving COVID-19 Vaccine

Staff ReporterEducation, Health, Science 0

President-elect Joe Biden received his first dose of the Pfizer-BioNTech COVID-19 vaccine on December 21st in front of cameras to help build confidence in the vaccine across the country.
Biden joined a list of high-profile politicians and millions of other font line healthcare workers and Seniors across the nation, vaccinated Dressed in a navy blue mock turtleneck and wearing two masks, Biden pushed up his left sleeve for the vaccination at ChristianaCare’s Christiana Hospital in Newark, Delaware.

“I’m doing this to demonstrate that people should be prepared, when it’s available, to take the vaccine. There’s nothing to worry about. I’m looking forward to the second shot,” Biden said shortly after receiving his vaccination.

“We owe these folks an awful lot. The scientists and the people who put this together and frontline workers, the people who were the ones who actually did the clinical work, it’s just amazing,” Biden said. “We owe you big, we really do.”

Biden’s vaccination comes as a second coronavirus vaccine, produced by Moderna, has begun to be distributed across the country, and as the death toll from the virus nears 320,000 Americans.
As the number of Covid-19 cases reported in the United States passed 18 million, the second vaccine given emergency authorization was being administered Monday for the first time outside of clinical trials.

One of the first people to get a public dose of the Moderna Covid-19 vaccine was a doctor in Texas who has gone to work, fighting the virus for 277 consecutive days. “This is like having gold,” Dr. Joseph Varon told CNN as he held a box of doses shortly before he was vaccinated. “I don’t cry, but I came very close … You know how many lives you can save with this?”

The president-elect said the Trump administration “deserves some credit” for getting the vaccine and distribution off the ground with Operation Warp Speed, but stressed that while the vaccines marked progress, the country needs to continue taking precautions to slow the spread of coronavirus, particularly around the upcoming holidays.

“I don’t want to sound like a sour note here, but I hope people listen to all of the experts and the Dr. Faucis on … talking about the need to wear masks during this Christmas and New Year’s holidays. Wear masks, socially distance. And if you don’t have to travel, don’t travel. Don’t travel. It’s really important because we’re still in the thick of this,” Biden said

Biden, 78, had long promised to take the vaccine if advised by Dr. Fauci to do so. In an interview with ABC’s “Good Morning America” last week, Fauci recommended Biden receive the vaccine as soon as possible.

“Dr. Fauci recommends I get the vaccine sooner than later. I want to just make sure we do it by the numbers, and we do it — but when I do it, you’ll have notice and we’ll do it publicly. Thank you,” Biden told reporters last Tuesday.

Vice President-elect Harris and her husband, incoming second gentleman Doug Emhoff, are also expected to receive the vaccine at a later date.

“Consistent with security and medical protocols, the Vice President will not receive the vaccine at the same time as the president. We expect she and Mr. Emhoff will receive their first dose of the vaccine the following week, and we will have additional details on that next week,” the incoming White House press secretary, Jen Psaki, said Friday.

Biden joins several political leaders who have received the vaccine, including Vice President Mike Pence, House Speaker Nancy Pelosi, Senate Majority Leader Mitch McConnell and several members of Congress.

One politician yet to take the vaccine is President Donald Trump, who has largely been out of public sight since the two COVID-19 vaccines have received emergency use authorization from the FDA.

As of Monday morning more than 614,000 Americans have received a vaccine shot, according to the US Centers for Disease Control and Prevention’s Covid Data Tracker.
Most Americans will have to wait months before getting their inoculations.

In the meantime, new infections, hospitalizations and deaths keep soaring, prompting health experts to urge the public to stay home this Christmas week.
“This is really not the time to be traveling,” epidemiologist Dr. Celine Gounder said.
But millions of airline passengers ignored such advice and traveled over the weekend.
Now travelers risk getting infected with a variant of coronavirus that might be even more contagious.

‘Christmas Star’ Brightens Up The Sky As Jupiter And Saturn Come Closer Than They Have In Centuries

Staff ReporterReligion, Science 0

If popular culture has taught us anything about the holidays, it’s that this is a season of reunions: a time when people conquer great distances and lengthy separations just to be together again. Usually, though, such stories involve cross-country trips — not the orbits of the two largest planets in our solar system.

This year is different.

On Dec. 21, Jupiter and Saturn — which are actually separated by more than 400 million miles —appeared closer to each other in the night sky than they have for centuries. Seen at the right hour, whether by telescope or the naked eye, the gas giants are separated by roughly a fifth of the diameter of the typical full moon. At this proximity, the planets will appear to touch or even form one large, brilliant star in the sky.

The spectacle is a curious effect of their orbits. Since Jupiter takes a little less than 12 years to circle the sun and Saturn takes more than 29, the planets appear to earthlings to meet roughly every 20 years, in what astronomers call a “great conjunction.” The last great conjunction occurred in May 2000, though its position in the sky at the time meant the average stargazer likely lost it in the glare of the sun.

But you’ll need to reach much further into the past to find the last instance such a conjunction was this close and this visible to stargazers. The Perth Observatory in Australia says that Jupiter and Saturn last approached this closely to each other in July 1623, but as with the conjunction in 2000, it was hard to spot.

“You’d have to go all the way back to just before dawn on March 4, 1226, to see a closer alignment between these objects visible in the night sky,” Patrick Hartigan, an astronomer at Rice University, explained in a statement last month.

There’s still another holiday connection at work here, beyond a simple coincidence of timing. Some astronomers, dating back to Johannes Kepler in the 17th century, have conjectured that the Star of Bethlehem that guided the three wise men to Jesus Christ’s birthplace in the Bible was a conjunction like the one set to appear later this month — although likely one involving different planets.

“Alignments between these two planets are rather rare, occurring once every 20 years or so, but this conjunction is exceptionally rare because of how close the planets will appear to one another,” said astronomer Patrick Hartigan, a professor of physics and astronomy at Rice University in Houston, in a statement.

Saturn and Jupiter began appearing close to each other this past summer, but this spectacle of proximity will be clearest beginning in mid-December.

“Look for them low in the southwest in the hour after sunset. And on December 21st, the two giant planets will appear just a tenth of a degree apart — that’s about the thickness of a dime held at arm’s length!” NASA explained earlier this month. “This means the two planets and their moons will be visible in the same field of view through binoculars or a small telescope. In fact, Saturn will appear as close to Jupiter as some of Jupiter’s moons.”

After the winter solstice, the two planets will appear to begin moving apart again.
Now, this sentimental holiday reunion is no Hallmark movie; if you miss it this year, don’t expect to see it again next December. Astronomers say there won’t be another great conjunction this close until 2080. (Courtesy: NPR.COM)

Thirumala-Devi Kanneganti led Team Develops Potential Strategy to Deal with COVID-19 Symptoms

Staff ReporterHealth, Science 0

A team led by Thirumala-Devi Kanneganti, vice chair of the St. Jude Department of Immunology, identified a previously unknown interaction between two messenger proteins that can unleash a cascade of inflammatory cell death, leading to tissue damage and multiple organ failure. The team also reported that two existing drugs based on neutralizing antibodies appear to disrupt this deadly process.

The study, published online in the journal Cell, comes as researchers around the globe race to develop therapies and vaccines to staunch a pandemic that, in less than one year, has killed some 1.2 million people and sickened millions more. With effective treatment options currently limited, doctors often rely on supportive care, including supplemental oxygen and mechanical breathing assistance, in their efforts to save patients.

“Understanding the pathways and mechanism driving this inflammation is critical to develop effective treatment strategies,” said Kanneganti, who was corresponding author of the study. “This research provides that understanding.”

The scientists, led by Thirumala-Devi Kanneganti, vice chair of immunology at St. Jude Children’s Research Hospital in Memphis, Tennessee, identified the drugs after discovering that the hyperinflammatory immune response associated with Covid-19 leads to tissue damage and multi-organ failure in mice by triggering inflammatory cell death pathways, the report said.

“Understanding the pathways and mechanism driving this inflammation is critical to develop effective treatment strategies,” Kanneganti, who was born in Telangana and earned her undergraduate degree at Kakatiya University in Warangal, said in the report.

“This research provides that understanding. We also identified the specific cytokines that activate inflammatory cell death pathways and have considerable potential for treatment of Covid-19 and other highly fatal diseases, including sepsis,” she said in the report.

Kanneganti worked with Bhesh Raj Sharma, Rajendra Karki and others at her lab for the research that helps increase understanding of the pathways and mechanism that drives COVID-19 inflammation so researchers can develop effective treatment strategies, it said.

The infection is marked by increased blood levels of multiple cytokines. These small proteins are secreted primarily by immune cells to ensure a rapid response to restrict the virus. Some cytokines also trigger inflammation, the release notes.

Kanneganti’s team focused on a select set of the most elevated cytokines in COVID-19 patients. The scientists showed that no single cytokine induced cell death in innate immune cells, it said.

The investigators showed that blocking individual cell death pathways was ineffective in stopping cell death caused by TNF-alpha and IFN-gamma, according to the report.

“The findings link inflammatory cell death induced by TNF-alpha and IFN-gamma to COVID-19,” said Kanneganti. “The results also suggest that therapies that target this cytokine combination are candidates for rapid clinical trials for treatment of not only Covid-19, but several other often fatal disorders associated with cytokine storm,” she said.

The work by Kanneganti’s team focused on cytokines, tiny proteins secreted primarily by immune cells. Infections involving SARS-CoV-2 — the virus that causes COVID-19 — can lead to increased blood levels of cytokines.

These proteins sometimes cause inflammation, and when they flood the bloodstream in dramatically increased levels, lead to what researchers call a “cytokine storm.” Other life-threatening disorders such as sepsis and hemophagocytic lymphohistiocytosis (HLH) can lead to the same immune system overreaction. But the exact pathways initiating the cytokine storms and subsequent inflammation have remained a mystery.

To find them, Kanneganti and her team examined the cytokines most often present in elevated levels in COVID-19 patients. After finding that no single cytokine caused cell death, the scientists tested 28 combinations of the proteins and discovered that just one pair, working together, did induce inflammation and tissue damage mirroring the symptoms of COVID-19.

Researchers further concluded that existing drugs, Remicade and Gamifant, which are used to treat such inflammatory diseases as Crohn’s disease and colitis prevented COVID-19 complications in laboratory models.

“The results also suggest that therapies that target this cytokine combination are candidates for rapid clinical trials for treatment of not only COVID-19, but several other often fatal disorders associated with cytokine storm,” Kanneganti said.

The study’s co-first authors are Rajendra Karki, PhD, and Bhesh Raj Sharman, PhD, of the Kanneganti laboratory. The other authors are Shraddha Tuladhar, Parimal Samir, Min Zheng, Balamurugan Sundaram, Balaji Banoth, R. K. Subbarao Malireddi, Patrick Schreiner, Geoffrey Neale, Peter Vogel and Richard Webby, of St. Jude; and Evan Peter Williams, Lillian Zalduondo and Colleen Beth Jonsson, of the University of Tennessee Health Science Center.

The research was supported in part by a grant from the National Institutes of Health (NIH); and ALSAC, the fundraising and awareness organization for St. Jude.

Moderna Seeking US, European Regulators To Approve Covid-19 Vaccination

Staff ReporterHealth, Science 0

Moderna Inc, which has reported its Covid-19 vaccine is 94 per cent effective, on Monday announced it is filing with US and European regulators for emergency use authorization. Moderna follows barely a week after Pfizer and its German partner BioNTech filed for US regulatory approval. By the end of 2020, Moderna expects to have approximately 20 million doses of its mRNA-1273 vaccine available in the U.S and is “on track to manufacture 500 million to 1 billion doses globally in 2021.

Moderna created its shots in collaboration with the U.S. National Institutes of Health and got a final batch of results over the weekend which show the vaccine is more than 94% effective. Moderna’s efficacy results are based on 196 Covid-19 cases in its huge U.S. study with more than 30,000 participants. Of the 196 cases, 185 were in participants who received the dummy shot and 11 who got the vaccine. Severe cases and one death were reported in participants who got the dummy shot.

Moderna expects to present its data to the US Food and Drug Administration on December 17. First up will be Pfizer and BioNTech, on December 10. Both Pfizer and Moderna are two-shot vaccines.

The US government’s vaccine management chief has said all systems are ready to deliver the vaccines to priority groups within 24 to 48 hours of FDA approval.  Government Model Suggests U.S. COVID-19 Cases Could Be Approaching 100 Million

The actual number of coronavirus infections in the U.S. reached nearly 53 million at the end of September and could be approaching 100 million now, according to a model developed by government researchers.

The model, created by scientists at the Centers for Disease Control and Prevention, calculated that the true number of infections is about eight times the reported number, which includes only the cases confirmed by a laboratory test.

Preliminary estimates using the model found that by the end of September, 52.9 million people had been infected, while the number of laboratory-confirmed infections was just 6.9 million, the team reported in the Nov. 25 issue of the journal Clinical Infectious Diseases.

“This indicates that approximately 84% of the U.S. population has not yet been infected and thus most of the country remains at risk,” the authors wrote.

Since then, the CDC’s tally of confirmed infections has increased to 12.5 million. So if the model’s ratio still holds, the estimated total would now be greater than 95 million, leaving about 71% of the population uninfected. The model attempts to account for the fact that most cases of COVID-19 are mild or asymptomatic and go unreported.

Scientists used studies looking for people who have antibodies to the coronavirus in their blood – an indication that they were infected at some time — to estimate how many infections went undetected. Some of these antibody studies have suggested that only about one in 10 coronavirus infections is reported.

The goal in creating the model was to “better quantify the impact of the COVID-19 pandemic on the healthcare system and society,” the authors wrote. The model also estimated that official counts do not include more than a third of the people hospitalized with COVID-19.

NPR (11/26, Hamilton) reported “the actual number of coronavirus infections in the U.S. reached nearly 53 million at the end of September and could be approaching 100 million now, according to a model developed by” Centers for Disease Control and Prevention researchers. The model “calculated that the true number of infections is about 8 times the reported number, which includes only the cases confirmed by a laboratory test.” NPR added, “Preliminary estimates using the model found that by the end of September, 52.9 million people had been infected, while the number of laboratory-confirmed infections was just 6.9 million, the team reported in…Clinical Infectious Diseases.”

-+=